{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T21:11:03Z","timestamp":1793653863989,"version":"4.5.1"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T00:00:00Z","timestamp":1715040000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.eclinm.2024.102655","type":"journal-article","created":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T19:13:48Z","timestamp":1717182828000},"page":"102655","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":66,"special_numbering":"C","title":["Once-daily upadacitinib versus placebo in adults with extensive non-segmental vitiligo: a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-ranging study"],"prefix":"10.1016","volume":"73","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0797-6570","authenticated-orcid":false,"given":"Thierry","family":"Passeron","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5468-4589","authenticated-orcid":false,"given":"Khaled","family":"Ezzedine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iltefat","family":"Hamzavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3249-8195","authenticated-orcid":false,"given":"Nanja","family":"van Geel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bethanee J.","family":"Schlosser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqiang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed M.","family":"Soliman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Rosmarin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John E.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2632-015X","authenticated-orcid":false,"given":"Heidi S.","family":"Camp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3916-2651","authenticated-orcid":false,"given":"Amit G.","family":"Pandya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eclinm.2024.102655_bib1","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1111\/jdv.18257","article-title":"Vitiligo prevalence and quality of life among adults in Europe, Japan and the USA","volume":"36","author":"Bibeau","year":"2022","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.eclinm.2024.102655_bib2","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/jamadermatol.2021.4724","article-title":"Prevalence of vitiligo among adults in the United States","volume":"158","author":"Gandhi","year":"2022","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.eclinm.2024.102655_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.790125","article-title":"Janus kinase inhibitors in the treatment of vitiligo: a review","volume":"12","author":"Qi","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.eclinm.2024.102655_bib4","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1007\/s13555-023-01001-2","article-title":"Comorbidity burden among patients with vitiligo in the United States: a large-scale retrospective claims database analysis","volume":"13","author":"Ezzedine","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.eclinm.2024.102655_bib5","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1111\/jdv.18129","article-title":"The humanistic burden of vitiligo: a systematic literature review of quality-of-life outcomes","volume":"36","author":"Picardo","year":"2022","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.eclinm.2024.102655_bib6","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.jid.2023.08.025","article-title":"Economic burden among patients with vitiligo in the United States: a retrospective database claims study","volume":"144","author":"Ezzedine","year":"2023","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.eclinm.2024.102655_bib7","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s40257-021-00631-6","article-title":"Psychosocial effects of vitiligo: a systematic literature review","volume":"22","author":"Ezzedine","year":"2021","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.eclinm.2024.102655_bib8","article-title":"How persistent stigma and discrimination keep people with visible skin diseases out of jobs: vitiligo in Brazil today","volume":"23","author":"Silveira","year":"2023","journal-title":"Lancet Reg Health Am"},{"key":"10.1016\/j.eclinm.2024.102655_bib9","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1001\/jamadermatol.2023.2787","article-title":"Mental health and psychosocial quality-of-life burden among patients with vitiligo: findings from the global VALIANT study","volume":"159","author":"Bibeau","year":"2023","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.eclinm.2024.102655_bib10","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1111\/jdv.16927","article-title":"Patients' perspective on current treatments and demand for novel treatments in vitiligo","volume":"35","author":"Narayan","year":"2021","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.eclinm.2024.102655_bib11","series-title":"Prescribing information","year":"2023"},{"key":"10.1016\/j.eclinm.2024.102655_bib12","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1365-2133.2012.11197.x","article-title":"Guidelines for the management of vitiligo: the European Dermatology Forum consensus","volume":"168","author":"Taieb","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.eclinm.2024.102655_bib13","doi-asserted-by":"crossref","first-page":"797","DOI":"10.3892\/etm.2021.10229","article-title":"Updates and new medical treatments for vitiligo","volume":"22","author":"Kubelis-L\u00f3pez","year":"2021","journal-title":"Exp Ther Med"},{"key":"10.1016\/j.eclinm.2024.102655_bib14","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1111\/jdv.19450","article-title":"Worldwide expert recommendations for the diagnosis and management of vitiligo: position statement from the international vitiligo task force-part 2: specific treatment recommendations","volume":"37","author":"Seneschal","year":"2023","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.eclinm.2024.102655_bib15","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1111\/jdv.19451","article-title":"Worldwide expert recommendations for the diagnosis and management of vitiligo: position statement from the international vitiligo task force part 1: towards a new management algorithm","volume":"37","author":"van Geel","year":"2023","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.eclinm.2024.102655_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.613056","article-title":"Targeting innate immunity to combat cutaneous stress: the vitiligo perspective","volume":"12","author":"Boniface","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.eclinm.2024.102655_bib17","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1038\/jid.2009.32","article-title":"Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients","volume":"129","author":"van den Boorn","year":"2009","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.eclinm.2024.102655_bib18","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1146\/annurev-immunol-100919-023531","article-title":"Vitiligo: mechanisms of pathogenesis and treatment","volume":"38","author":"Frisoli","year":"2020","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.eclinm.2024.102655_bib19","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s41927-018-0031-x","article-title":"In\u00a0vitro and in\u00a0vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)","volume":"2","author":"Parmentier","year":"2018","journal-title":"BMC Rheumatol"},{"key":"10.1016\/j.eclinm.2024.102655_bib20","series-title":"Prescribing information","year":"2023"},{"key":"10.1016\/j.eclinm.2024.102655_bib21","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/bjd.14208","article-title":"Validation of the vitiligo noticeability scale: a patient-reported outcome measure of vitiligo treatment success","volume":"174","author":"Batchelor","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.eclinm.2024.102655_bib22","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1056\/NEJMoa2118828","article-title":"Two phase 3, randomized, controlled trials of ruxolitinib cream for vitiligo","volume":"387","author":"Rosmarin","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.eclinm.2024.102655_bib23","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jaad.2022.11.005","article-title":"Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: a randomized phase 2b clinical trial","volume":"88","author":"Ezzedine","year":"2023","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.eclinm.2024.102655_bib24","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1016\/S0140-6736(21)00588-2","article-title":"Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials","volume":"397","author":"Guttman-Yassky","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.eclinm.2024.102655_bib25","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1136\/annrheumdis-2020-218510","article-title":"Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme","volume":"80","author":"Cohen","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.eclinm.2024.102655_bib26","doi-asserted-by":"crossref","first-page":"e003392","DOI":"10.1136\/rmdopen-2023-003392","article-title":"MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis","volume":"9","author":"Charles-Schoeman","year":"2023","journal-title":"RMD Open"},{"key":"10.1016\/j.eclinm.2024.102655_bib27","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jaci.2022.09.023","article-title":"Safety of upadacitinib in moderate-to-severe atopic dermatitis: an integrated analysis of phase 3 studies","volume":"151","author":"Guttman-Yassky","year":"2023","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.eclinm.2024.102655_bib28","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1016\/S0140-6736(21)00589-4","article-title":"Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"397","author":"Reich","year":"2021","journal-title":"Lancet"}],"updated-by":[{"DOI":"10.1016\/j.eclinm.2025.103167","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000}}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537024002347?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537024002347?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T11:00:25Z","timestamp":1744974025000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537024002347"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":28,"alternative-id":["S2589537024002347"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2024.102655","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Once-daily upadacitinib versus placebo in adults with extensive non-segmental vitiligo: a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-ranging study","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2024.102655","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102655"}}